Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > ARCHIVE
ARCHIVE
- Pfizer Obtains Approval for Generics of 14 APIs
August 1, 2011
- US FDA Announces Draft Guidance for Simultaneous Development of Therapeutics and Companion Diagnostic Devices
August 1, 2011
- Daiichi Sankyo Espha to Deal with Both Long-listed Products, Generics
August 1, 2011
- Biosimilars Optimize Healthcare Costs: JSGM Seminar
August 1, 2011
- AZ, NCC Announce Comprehensive Agreement for Development of Anticancer Drugs
August 1, 2011
- Eisai Launches Halaven in Japan; Product to Be Detailed by All 1,400 MRs
August 1, 2011
- Volume-based Generics Market Share Up to 23.0% in FY 2010: JGA
August 1, 2011
- Shionogi Starts 4th PIII Study of the HIV Treatment S-349572
August 1, 2011
- Daiichi Sankyo Launches Lixiana for Prevention of VTE
August 1, 2011
- JGA Compiles Model Corporate Ethics Standards
August 1, 2011
- Takeda to Beef Up Its OTC Drugs Business in Asia
August 1, 2011
- RaQualia Listed on JASDAQ; Aims to Raise ¥6.3 Bil.
August 1, 2011
- MTPC Ordered to Stop Operations for 10 Days at Subsidiary Plant
August 1, 2011
- Japan Federation of Non-prescription Medicines Industry Set Up by 5 Organizations
August 1, 2011
- Astellas to Drive Business in Emerging Markets Based on GCL Strategy: Vice Deputy Chairman Ishii
August 1, 2011
- Council Starts Discussing How to Realize Proposed Social Security/Tax Reform Plan
August 1, 2011
- 3 Vaccines Judged to Be Safe “at Present Time”: PAFSC Study Groups
August 1, 2011
- Chugai: Operating Profits Up 27% in 1st Half
August 1, 2011
- EMA Asks Takeda to Revise Package Inserts for Pioglitazone Medicines Due to Risk of Bladder Cancer
August 1, 2011
- PAFSC Subcommittee Recommends Classification of 4 Crude Drugs as Class 2 OTC Drugs
August 1, 2011
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…